labeled "Rh Positive." If the test is negative, the results shall be confirmed by further testing which shall include tests for the "weak D (formerly D-)." Blood may be labeled "Rh Negative" if further testing is negative. Units testing positive after additional more specific testing shall be labeled as "Rh Positive." Only Anti-Rh Blood Grouping Reagents licensed under, or that otherwise meet the requirements of, this subchapter shall be used, and the technique used shall be that for which the reagent is specifically designed to be effective.

(d) Sterility test. Whole Blood intended for transfusion shall not be tested for sterility by a method that entails entering the final container before the blood is used for transfusion.

(e) Inspection. Whole Blood shall be inspected visually during storage and immediately prior to issue. If the color or physical appearance is abnormal or there is any indication or suspicion of microbial contamination the unit of Whole Blood shall not be issued for transfusion.

(f) Test for communicable disease agents. Whole Blood shall be tested for evidence of infection due to communicable disease agents as required under §610.40 of this chapter.

§640.6 Modifications of Whole Blood.

Upon approval by the Director, Center for Biologics Evaluation and Research, of a supplement to the biologics license application for Whole Blood a manufacturer may prepare Whole Blood from which the antihemophilic factor has been removed, provided the Whole Blood meets the applicable requirements of this subchapter and the following conditions are met:

(a) The antihemophilic factor shall be removed in accordance with paragraphs (a), (b), and (c) of §640.52.

(b) Although the closed system between the red blood cells and plasma shall be maintained, the red blood cells shall be maintained between 1 and 6 °C at all times, including that time when the plasma is being frozen for removal of the antihemophilic factor.

Subpart B—Red Blood Cells

§640.10 Red Blood Cells.

The proper name of this product shall be Red Blood Cells. The product is defined as red blood cells remaining after separating plasma from human blood.

§640.11 General requirements.

(a) Storage. Immediately after processing, the Red Blood Cells shall be placed in storage and maintained at a temperature between 1 and 6 °C.

(b) Inspection. The product shall be inspected immediately after separation of the plasma, periodically during storage, and at the time of issue. The product shall not be issued if there is any abnormality in color or physical appearance or if there is any indication of microbial contamination.

§640.12 Suitability of donor.

The source blood for Red Blood Cells shall be obtained from a donor who meets the criteria for donor suitability prescribed in §640.3.

§640.13 Collection of the blood.

(a) The source blood shall be collected as prescribed in §640.4.

(b) Source blood may also be derived from Whole Blood manufactured in accordance with applicable provisions of this subchapter.

§640.14 Testing the blood.

Blood from which Red Blood Cells are prepared shall be tested as prescribed
in §610.40 of this chapter and §640.5 (a), (b), and (c).

[30 FR 117, Jan. 5, 1988, as amended at 66 FR 31165, June 11, 2001]

§ 640.15 Segments for testing.

Segments collected in integral tubing shall meet the following standards:
(a) One or more segments shall be provided with each unit of Whole Blood or Red Blood Cells when issued or reissued.
(b) Before they are filled, all segments shall be marked or identified so as to relate them to the donor of that unit of red cells.
(c) All segments accompanying a unit of Red Blood Cells shall be filled at the time the blood is collected or at the time the final product is prepared.

[66 FR 40890, Aug. 6, 2001]

§ 640.16 Processing.

(a) Separation. Within the timeframe specified in the directions for use for the blood collecting, processing, and storage system used, Red Blood Cells may be prepared either by centrifugation, done in a manner that will not tend to increase the temperature of the blood, or by normal undisturbed sedimentation. A portion of the plasma sufficient to insure optimal cell preservation shall be left with the red cells except when a cryoprotective substance or additive solution is added for prolonged storage.
(b) Sterile system. All surfaces that come in contact with the red cells shall be sterile and pyrogen-free.
(c) Final containers. Final containers used for Red Blood Cells shall be the original blood containers unless the method of processing requires a different container. The final container shall meet the requirements for blood containers prescribed in §640.2(c). At the time of filling, if a different container is used, it shall be marked or identified by number or other symbol so as to relate it to the donor of that unit of red cells.


Subpart C—Platelets

§ 640.20 Platelets.

(a) Proper name and definition. The proper name of this product shall be Platelets. The product is defined as platelets collected from one unit of blood and resuspended in an appropriate volume of original plasma, as prescribed in §640.24(d).

(b) Source. The source material for Platelets is plasma which may be obtained by whole blood collection or by plateletheraphesis.


§ 640.21 Suitability of donors.

(a) Whole blood donors shall meet the criteria for suitability prescribed in §640.3.
(b) [Reserved]
(c) Platelethapheresis donors must meet the criteria for suitability as prescribed in §§640.3 and 640.63(c)(6) or as described in an approved biologics license application (BLA) or an approved